Risk of Upper Gastrointestinal Ulcers in Patients With Osteoarthritis Receiving Single-Tablet Ibuprofen/Famotidine Versus Ibuprofen Alone: Pooled Efficacy and Safety Analyses of Two Randomized, Double-Blind, Comparison Trials

References

• . Lawrence RC, Felson DT, Helmick CG, . Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26–35
   PubMed Web of Science ®Google Scholar
• . Murphy LB, Helmick CG, Schwartz TA, . One in four people may develop symptomatic hip osteoarthritis in his or her lifetime. Osteoarthritis Cartilage. 2010;18(11):1372–1379
   PubMed Web of Science ®Google Scholar
• . Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull WHO. 2003;81(9):646–656
   PubMed Web of Science ®Google Scholar
• . Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Rheum Dis Clin North Am. 2008;34(3):51529
   Web of Science ®Google Scholar
• . Murphy L, Helmick CG. The impact of osteoarthritis in the United States: a population-health perspective. Am J Nurs. 2012;112(3):S13–S19
   PubMed Web of Science ®Google Scholar
• . Jordan JM, Helmick CG, Renner JB, . Prevalence of knee symptoms and radiographic and symptomatic knee osteoarthritis in African Americans and Caucasians: the Johnston County Osteoarthritis Project. J Rheumatol. 2007;34(1):172–180
   PubMed Web of Science ®Google Scholar
• . Laska EM, Sunshine A, Marero I, . The correlation between blood levels of ibuprofen and clinical analgesic response. Clin Pharm Ther. 1986;40(1):1–7
   PubMed Web of Science ®Google Scholar
• . Bradley JD, Brandt KD, Katz BP, . Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med. 1991;325(2):87–91
   PubMed Web of Science ®Google Scholar
• . US Food and Drug Administration. FDA briefing document on non-steroidal anti-inflammatory drugs and cardiovascular thrombotic risk. Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management, Advisory Committee, February 10–11, 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM383180.pdf. Accessed February 14, 2014
   Google Scholar
• . Adatia A, Rainsford KD, Kean WF. Osteoarthritis of the knee and hip. Part II: therapy with ibuprofen and a review of clinical trials. J Pharm Pharmacol. 2012;64:626–636
   PubMed Web of Science ®Google Scholar
• . Puopolo A, Boice JA, Fidelholtz MD, . A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. Osteoarthritis Cartilage. 2007;15(12):1348–1356
   PubMed Web of Science ®Google Scholar
• . Wiesenhutter CW, Boice JA, Ko A, . Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2005;80(4):470–479
   PubMed Web of Science ®Google Scholar
• . Day R, Morrison B, Luza A, . A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch Intern Med. 2000;160(12):1781–1787
   PubMedGoogle Scholar
• . Goldstein JL, Hochberg MC, Fort JG, . Clinical trial: the incidence of NSAID-associated endoscopic gastric ulcers in patients treated with PN 400 (naproxen plus esomeprazole magnesium) vs. enteric-coated naproxen alone. Aliment Pharmcol Ther. 2010;32(3):401–413
   PubMed Web of Science ®Google Scholar
• . Laine L, Kivitz AJ, Bello AE, . Double-blind randomized trials of single-tablet ibuprofen/high-dose famotidine vs. ibuprofen alone for reduction of gastric and duodenal ulcers. Am J Gastroenterol. 2012;107(3):379–386
   PubMed Web of Science ®Google Scholar
• . Schiff M, Peura D. HZT-501 (DUEXIS®; ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Expert Rev Gastroenterol Hepatol. 2012;6(1):25–35
   PubMed Web of Science ®Google Scholar
• . Goldstein JL, Howard KB, Walton SM, . Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol. 2006;4(11):1337–1345
   PubMed Web of Science ®Google Scholar
• . Coyne KS, Margolis MK, Cappelleri JC, . Prevalence of gastroprotective agent (GPA) use in adults with arthritis in the United States. Curr Med Res Opin. 2013;29(5):421–433
   PubMed Web of Science ®Google Scholar
• . Lanas A, Polo-Tomas M, Roncales P, . Prescription of and adherence to nonsteroidal anti-inflammatory drugs and gastroprotective agents in at-risk gastrointestinal patients. Am J Gastroenterol. 2012;107(5):707–714
   PubMed Web of Science ®Google Scholar
• . van Soest EM, Sturkenboom MC, Dieleman JP, . Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. Aliment Pharmacol Ther. 2007;26(2):265–275
   PubMed Web of Science ®Google Scholar
• . Working Group on the Summit on Combination Therapy for CVD. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. Eur Heart J. 2014;35(6):353–364
   PubMed Web of Science ®Google Scholar
• . Pan F, Chernew ME, Fendrick AM. Impact of fixed-dose combination drugs on adherence to prescription medications. J Gen Intern Med. 2008;23(5):611–614
   PubMed Web of Science ®Google Scholar
• . Yeomans N. A clinical approach to management of patients with non-steroidal anti-inflammatory gastropathy. Ital J Gastroenterol Hepatol. 2009;31( Suppl 1):S89–S92
   Google Scholar
• . Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Gastrointestinal Drugs Advisor Committee (GIDAC), Advisory Meeting, Hilton Washington DC/North; Gaithersburg, VA; November 4, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM237496.pdf and http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM235452.pdf
   Google Scholar
• . Lanza FL, Royer GL, Nelson RS, . The effects of ibuprofen, indomethacin, aspirin, naproxen, and placebo on the gastric mucosa of normal volunteers. A gastroscopic and photographic study. Dig Dis Sci. 1979;24:823–828
   PubMed Web of Science ®Google Scholar
• . Larkai EN, Smith JL, Lidsky MD, . Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic nonsteroidal anti-inflammatory drug use. Am J Gastroenterol. 1987;82:1153–1158
   PubMed Web of Science ®Google Scholar
• . Hawkey CJ, Weinstein WM, Stricker K, . Clinical trial: comparison of the gastrointestinal safety of lumiracoxib with traditional nonselective nonsteroidal anti-inflammatory drugs early after the initiation of treatment—findings from the Therapeutic Arthritis Research and Gastrointestinal Event Trial. Aliment Pharmacol Ther. 2008;27:838–845
   PubMed Web of Science ®Google Scholar
• . Lanza FL. Endoscopic studies of gastric and duodenal injury after the use of ibuprofen, aspirin, and other non-steroidal anti-inflammatory agents. Am J Med. 1984;77:19–24
   PubMed Web of Science ®Google Scholar
• . Brown TJ, Hooper L, Elliott RA, . A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modeling. Health Technol Assess. 2006;10(38):iii–xiii, 1–183
   Web of Science ®Google Scholar
• . Ray WA, Chung CP, Stein CM, . Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology. 2007;133(3):790–798
   PubMed Web of Science ®Google Scholar
• . Spiegel BM, Chiou CF, Ofman JJ. Minimizing complications from non-steroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups. Arthritis Rheum. 2005;53(2):185–197
   PubMed Web of Science ®Google Scholar
• . Rostom A, Dube C, Wells GA, . Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;4:CD002296
   PubMedGoogle Scholar
• . Niculescu L, Li C, Huang J, Mallen S. Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2009;25(3):729–740
   PubMed Web of Science ®Google Scholar
• . Silverstein FE, Faich G, Goldstein JL, . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247–1255
   PubMed Web of Science ®Google Scholar
• . Ofman JJ, Maclean CH, Straus WL, . Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2003;49(4):508–518
   PubMed Web of Science ®Google Scholar
• . Yilmaz H, Gurel S, Ozdemir O. The use and safety profile of non-steroidal antiinflammatory drugs among Turkish patients with osteoarthritis. Turk J Gastroenterol. 2005;16(3):138–142
   PubMedGoogle Scholar
• . Angiolillo DJ, Datto C, Raines S, Yeomans ND. Impact of concomitant low-dose aspirin on the safety and tolerability of naproxen and esomeprazole magnesium delayed-release tablets in patients requiring chronic nonsteroidal anti-inflammatory drug therapy: an analysis from 5 Phase III Studies. J Thromb Thrombolysis. 2014;38(1):11–23
   PubMed Web of Science ®Google Scholar
• . Laine L, Connors L, Griffin MR, . Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. Aliment Pharmacol Ther. 2009;30(7):767–774
   PubMed Web of Science ®Google Scholar
• . Moore RA, Derry S, Phillips CJ, McQuay HJ. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice. BMC Musculoskelet Disord. 2006;7(10):79–91
   PubMed Web of Science ®Google Scholar
• . Wilcox CM, Cryer B, Triadafilopoulos G. Patterns of use and public perception of over-the-counter pain relievers: focus on nonsteroidal antiinflammatory drugs. J Rheumatol. 2005;32(11):2218–2224
   PubMed Web of Science ®Google Scholar
• . Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167(6):540–550
   PubMedGoogle Scholar
• . Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm. 2003;60(7):657–665
   PubMed Web of Science ®Google Scholar
• . McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288(22):2868–2879
   PubMed Web of Science ®Google Scholar
• . van Dulmen S, Sluijs E, van DL, . Patient adherence to medical treatment: a review of reviews. BMC Health Serv Res. 2007;7(4):55–67
   PubMed Web of Science ®Google Scholar
• . Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120(8):713–719
   PubMed Web of Science ®Google Scholar
• . Sturkenboom MC, Burke TA, Tangelder MJ, . Adherence to proton pump inhibitors or H2-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2003;18(11–12):1137–1147
   PubMed Web of Science ®Google Scholar
• . Kuan R, Holt RJ, Johnson KE, . Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis. Clin Ther. 2013;35:321–332
   PubMed Web of Science ®Google Scholar